How are medical isotopes changing the way we diagnose and treat disease?
Medical isotopes enable earlier diagnosis and targeted therapy for diseases like cancer, resulting in shorter hospital stays and fewer side effects for patients across the country, compared to some traditional treatments. Diagnostic imaging, such as radioisotope-powered PET scans, can help diagnose diseases sooner, with applications in oncology, cardiology, mental health research, and more. Looking at therapy, isotopes such as Lutetium-177 offer targeted treatments for diseases like prostate cancer and neuroendocrine tumours.
As global demand for medical isotopes continues to grow, where do you see Canada’s biggest opportunities?
Canada has been a leader in the global isotope sector for nearly a century, and we continue to be well-placed to build on that legacy. As demand rises and promising clinical trials evolve globally, Canada has a unique opportunity to reshore critical parts of the value chain, including investing in isotope processing capabilities. With a shifting global geopolitical landscape, ensuring a resilient domestic supply of isotopes in Canada is critical.
How important is collaboration between industry, healthcare providers, researchers, and government in advancing nuclear medicine?
Collaboration is critical to advancing Canada’s isotope leadership. As the Government of Canada works to develop its newly announced comprehensive Radioisotope Strategy, the importance of collaboration takes on a new significance. Industry, academic, and clinical leaders must be involved in the process from the outset due to the unique, cross-disciplinary nature of this industry.
Looking ahead, what excites you most about the future of nuclear medicine?
The field of nuclear medicine is rapidly evolving, and exciting developments are constantly emerging. Among the most exciting is the promise of theranostics – the combination of THERA-py and diag-NOSTICS. Theranostic radiopharmaceuticals enable the precise detection of cancer within the body, while simultaneously delivering targeted therapy that targets cancer cells, leaving healthy tissue behind. Theranostics could become an increasingly important pillar of oncology, making it one of the most exciting and hopeful opportunities in our industry.
